Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Sarcoma, Myeloid 1Sarcoma 1Rhabdomyosarcoma 1Myeloproliferative Disorders 1Malignant mesenchymal tumor 1Leukemia, Myeloid, Acute 1Ganglioneuroblastoma 1Blast Crisis 1

Interventions

venetoclax 28Cytarabine 25Azacitidine 23Specimen Handling 21fludarabine 15Biopsy 13Injections 12Daunorubicin 11Cyclophosphamide 11fludarabine phosphate 10decitabine and cedazuridine drug combination 9Whole-Body Irradiation 9CPX-351 8Mycophenolic Acid 7Idarubicin 7Granulocyte Colony-Stimulating Factor 7Gemtuzumab 7ivosidenib 6Tacrolimus 6Stem Cell Transplantation 6Filgrastim 6Busulfan 6enasidenib 5X-Rays 5Melphalan 5Etoposide 5Decitabine 5Cyclosporine 5ruxolitinib 4olutasidenib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × Dexrazoxane × 30 days × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡